A Director at Intrexon is Exercising Options

Yesterday, a Director at Intrexon, Steven Frank, exercised options of Intrexon for $23.51K. The options were close to expired and Steven Frank retained stocks.

Following this transaction Steven Frank’s holding in the company was increased by 4.94% to a total of $2.55 million. In addition to Steven Frank, one other XON executive reported Buy trades in the last month.

Based on Intrexon’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $46.02 million and GAAP net loss of $39.69 million. In comparison, last year the company earned revenue of $46 million and had a GAAP net loss of $44.14 million. The company has a one-year high of $26.99 and a one-year low of $10.26. Currently, Intrexon has an average volume of 1.28M.

Seven different firms, including Dougherty and Griffin, currently also have a Buy rating on the stock.

The insider sentiment on Intrexon has been positive according to 37 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intrexon Corp. operates as a biotechnology company. The company engages in the field of synthetic biology, which is an emerging discipline that applies engineering principles to biological systems.